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Central Message
Treatment decision-making in thoracic aortic
aneurysms of the ascending aorta is complex
both with regard to the timing of surgery and
with regard to the invasive treatment strategy.Treatment decision-making in thoracic aortic aneurysms of the ascending
aorta is complex both with regard to the timing of surgery and with regard to
the invasive treatment strategy. From a clinician perspective, it is seen as
important to balance the risks of watchful waiting D15X Xversus preventive surgery
and to choose a surgical treatment strategy that will result in the lowest early
and late event occurrence. The current clinical practice guidelines and
reported outcomes after surgery suggest that there are many gray zones in
determining the optimal timing and the type of intervention. From a patient
perspective, quality of life and in particular minimization of anxiety and
depression due to the fear of aortic rupture or the potential occurrence of
complications related to the different treatment strategies are important to
consider. Quality of life studies and evidence on the importance of patient
participation in decision-making make a strong case for evidence-based
shared treatment decision in this complex patient group.
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Keywords: Thoracic aortic aneurysm surgery, Shared decision makingThoracic aortic aneurysms (TAA) result from progressive
dilatation of the thoracic aorta and confer a risk for aortic dis-
section or rupture, which is associated with signiﬁcant morbid-
ity and mortality. The incidence of TAAs in the general
population is difﬁcult to estimate because the disease is usually
“silent.” The main concern of TAA is an acute dissection of the
aorta, which represents an emergent condition associated with
an exceptionally high D16X Xmortality rate in the ﬁrst 48 hours after
symptom onset, particularly in patients who are not immedi-
ately referred for surgical treatment to centers with expertise in
this procedure. The goal of treatment is to prevent aortic dis-
section, because this is associated with poor outcome. The
indication for preventive surgery is presently based on the
underlying diagnosis (reﬂecting the “frailty” of the vessel wall)
and aorta diameter size (representative of the wall tension). It
is crucial that the risk for “prophylactic” aortic replacementDepartment of Cardiothoracic Surgery, Erasmus University Medical
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https://doi.org/10.1053/j.semtcvs.2019.05.032should be no greater than the risk for dissection. Also, longer
term complications associated with surgery should be taken
into account in the decision on timing of surgery and on the
preferred surgical strategy.
Many TAA patients experience high levels of stress, afraid
that their aorta might rupture. Treatment decision-making is
often complex, both when it comes to deciding on the timing
of intervention and on the preferred surgical strategy. Better
consideration of patient preferences in these treatment deci-
sion-making processes and reliable patient information con-
veyance may greatly enhance patient’s quality of life (QOL)
and participation in treatment decision-making.
This perspective will focus on treatment decision-making in
TAA of the ascending aorta, ﬁrst focusing on the clinician per-
spective: the current guidelines and reported outcomes after
surgery. Second, the patient perspective will be addressed
including QOL outcomes and the importance of patient partic-
ipation in decision-making. Finally, the case for evidence-based
shared treatment decision-making in TAA is made.
THE CLINICIAN PERSPECTIVE
Treatment decision-making from a clinical perspective is
built upon evidence on outcomes after different treatment
options and application of this knowledge to the unique state
and circumstances of the patient. The internationally most1Elsevier Inc. This is an open access article under the
c-nd/4.0/)
Table 1. Pooled Characteristics and Outcomes of VSRR and Bentall Procedure
VSRR Bentall
Pooled Data Range Pooled Data Range
Total patient number 4777 32430 7629 40675
Surgical period 19882012 19682012
Mean age (years) 51 2963 49.8 2965
Gender, male (%) 71 5785 76.3 5591
Type A dissection (%) 10.5 033 15.3 039
Connective tissue disease (%) 23.9 0100 22.6 0100
Bicuspid aortic valve (%) 14.1 033 24.9 4100
Prior cardiac operation (%) 4.49 212 16.2 17
Pooled Data 95% CI Pooled Data 95% CI
Early mortality (%) 2.2 1.72.6 5.6 5.06.0
Overall late mortality (%/ D1X Xy) 1.53 1.191.96 2.02 1.772.31
Late reoperation (%/ D2X Xy) 1.32 1.01.74 0.30 0.220.41
Late hemorrhage (%/ D3X Xy) 0.23 0.130.42 0.64 0.470.87
Late thromboembolism (%/ D4X Xy) 0.41 0.220.77 0.77 0.601.00
Late endocarditis (%/D5X Xy) 0.23 0.110.51 0.39 0.330.46
Late MAVRE (%/D6X Xy) 1.66 1.242.23 2.66 2.173.24
Bentall, Bentall procedure; D7X Xy, patient-years; VSRR, valve-sparing root replacement; MAVR, major adverse valve related eventD8X X.
Early: <30 days; Late >30 days; Late reoperation: reoperation on aortic valve.
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Heart Association (AHA) and American College of Cardiology
Foundation “Guidelines for the Diagnosis and Management of
Patients with Thoracic Aortic Disease”1 and the 2014 European
Society of Cardiology (ESC) “Guidelines on the diagnosis and
treatment of aortic diseasesD17X X”.2 The AHA guidelines recommend
surgery at an ascending aortic or aortic sinus diameter >5.5
cm, the ESC guidelines >5.0 cm. Both recommend surgery at
smaller diameters in case of genetically mediated disorders; the
AHA guidelines also include patients who require aortic valve
surgery or progression of aortic diameter >0.5 cm/y. The ESC
guidelines add that lower thresholds for intervention may be
considered (IIB) according to small BSA, rapid progression,
aortic valve regurgitation, planned pregnancy, or patient pref-
erence. Most of the recommendations in both guidelines have
level of evidence C. In the 2014 ESC guidelines, 80% of the
recommendations are consensus based. The 2014 ESC guide-
lines also provide an overview of the major knowledge gaps.
These include the accuracy and reproducibility of aortic meas-
urements, data on female patients, randomized studies for the
optimal timing for preventive intervention, epidemiological
data on acute aortic syndrome, and the value of biomarkers.
This reﬂects the lack of knowledge on thoracic aortic disease
and the urgent need for more research.
In recent years, systematic reviews on reported outcomes
after aortic root surgery have been published in an effort to
improve scientiﬁc quality of data and identify the knowledge
gaps. Mookhoek et al performed a systematic review including
meta-analysis of reported results of mechanical Bentall opera-
tions over a surgical period of 44 years, including 46 studies in2 Seminars in Ththeir analysis.3 Arabkhani et al performed a systematic review
including meta-analysis of reported results of valve-sparing
aortic root replacement, including 31 studies in their analysis.4
The pooled characteristics and outcomes of these 2 studies are
displayed in Table 1. Both studies report that heterogeneous
reporting in the included studies limits the meta-analyses and
argue the need for standardizing data reporting, and collabora-
tion of centers worldwide.
A systematic review and meta-analysis on aortic root surgery
in patients with Marfan syndrome was reported by Flynn
et al.5 It compared pooled outcomes of valve-sparing root
replacement (VSRR, N = 1352) with the Bentall procedure
(N = 1624) from 23 studies (published 19992017). Pooled
early mortality was 0.3%/patient-year (95% conﬁdence interval
[CI] 0.20.5%/patient-year) for Bentall, and 0.1%/patient-year
(95% CI 00.2%) for VSRR. Pooled late mortality was 1.8%/
patient-year (95% CI 1.12.5%) in Bentall, and 0.5% (95% CI
0.30.7%) in VSRR. Although it was reported that in compari-
son to the Bentall procedure VSRR was associated with reduced
risk of thromboembolism, late hemorrhagic complications and
endocarditis and no signiﬁcant difference in reintervention
rates between VSRR and D18X Xthe Bentall procedure, these results
need to be interpreted with caution as no details were given
about potential differences in patient characteristics between
the populations and the follow-up duration of the studies was
limited.
Worth mentioning is a new, lesser invasive preventive treat-
ment modality has been developed for aortic root aneurysm in
the last decade: Personalised external aortic root support
(PEARS). PEARS is a polymer mesh sleeve for the preventionoracic and Cardiovascular Surgery  Volume 00, Number 00
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individually manufactured for each patient using 3D imaging.
PEARS is employed at smaller aortic root diameters than con-
temporary surgery in patients who do not require intervention
on the aortic valve, and is wrapped around the patients’ aortic
root and ascending aorta without opening the aorta. Cardio-
pulmonary bypass can be omitted, making the procedure less
invasive than contemporary aortic root surgery. Izgi et al
reported a prospective series of 24 consecutive Marfan syn-
drome patients who received PEARS. MRI measured aortic
growth during a mean follow-up of 6.3 years showed no
increase in aortic root and ascending aorta diameters, but a sig-
niﬁcant increase in descending aorta diameter (which is not
covered by PEARS).6 A histologic study of PEARS-covered
aorta in a Marfan syndrome patient who died 4.5 years after
implantation showed that the supported part of the aorta had a
normal histologic appearance.7 Although still in the pioneer
phase and lacking long-term outcome data, PEARS represents
a promising treatment modality that toward the future will
allow patients and doctors to choose for a lesser invasive surgi-
cal procedure earlier on in the disease process.
The evidence on clinical outcomes after different invasive
treatments as described above illustrates that morbidity and
mortality after aortic root surgery are considerable and that
both the occurrence and the nature of the complications differ
between the different surgery options. After mechanical Bentall
anticoagulation-related complications are more common while
bioprosthetic Bentall and valve-sparing aortic root surgery the
hazard of reinterventions prevails. In case of PEARS, it remains
uncertain whether preventive and less invasive surgery earlier
on during disease progression provides a durable solution.
There are still a lot of knowledge gaps to be ﬁlled. International
collaboration and standardized outcome reporting are required
to ﬁll these gaps. The international AVIATOR registry that was
initiated in 2013 will be of great value in this respect.8
THE PATIENT PERSPECTIVE
To come to a truly patient-centered treatment decision, it
requires consideration of evidence on outcomes, the patient’s
unique state, and circumstances but to also taking the patient
perspective into account and involving the patient in decision-
making. This sounds logical but clinical practice shows that this
is not easy. It requires consideration of patient QOL, patient val-
ues and goals in life, and eliciting patient preferences in relation
to the available treatment options. What do we know about
QOL in patients with TAAs? And how can we elicit patient pref-
erences and involve patients in decision-making?
In a previous review by De Heer et al, QOL after thoracic
aortic surgery was discussed in detail.9 It illustrated that lim-
ited and only observational data are available concerning QOL
after thoracic aortic surgery. Although an older study by Ols-
son in 1999 showed signiﬁcantly worse health-related QOL
outcomes for patients who had thoracic aortic surgery com-
pared to the general population, an updated study in 2013
showed comparable QOL.10,11 This may be due to advances inSeminars in Thoracic and Cardiovascular Surgery  Volume 00cardiac surgery and quality of cardiovascular care throughout
the years and is in line with other contemporary studies includ-
ing a systematic review by Jarral et al that found QOL in tho-
racic aortic surgery patients to be comparable to the general
population.1214
There may however be differences in QOL between aortic
root surgery strategies: observational evidence suggests that
QOL after surgery is signiﬁcantly worse in most of the domains
of the SF-36 in patients with composite graft rofot replacement
versus D19X X valve-sparing surgery. Additionally, composite graft
patients report to be signiﬁcantly more disturbed by valve
sound, more afraid that their valve would fail and assign a
lower score to their overall condition.15 This is in line with
ﬁndings from a study by Aicher et al that compared QOL in
mechanical aortic valve recipients D20X Xversus valve-sparing and
pulmonary autograft replacement.16 There is no evidence that
there is a difference between mechanical D21X Xversus biological com-
posite root replacement.17
For patients with Marfan syndrome, there seems to be a sig-
niﬁcantly reduced QOL compared to the general population.
Goldﬁnger et al recently reported on QOL in the GENTAC
cohort and showed that health-related QOL is below the norm
in patients with Marfan syndrome, conﬁrming previous obser-
vations.18 Interestingly, determinants of health-related QOL in
this US cohort are mostly related to health insurance and socio-
economic factors and not to aspects of Marfan. Moon et al
reported anxiety and depression in 64% and 72%, respectively,
D22X Xof Marfan syndrome patients visiting a tertiary care hospital in
Seoul, South Korea.19 They also found that QOL (SF-36) is
affected signiﬁcantly by social support, disease-related factors,
and biobehavioral factors, and underline the need for compre-
hensive interventions addressing these factors.
Given these observations, the notion arises that it is impor-
tant to consider QOL as a factor in treatment selection for TAA
surgery—in particular for those with Marfan syndrome—and
elicit patient preferences with regard to treatment selection in
order to come to an evidence-based and patient-centered treat-
ment decision that best reﬂects the patient’s values and goals in
life.
THE CASE FOR EVIDENCE-BASED SHARED
TREATMENT DECISION-MAKING IN THORACIC
AORTIC ANEURYSM
The ESC guidelines mention the consideration of patient
preferences in aortic aneurysm treatment decision-making,2
and of course patients should be fully informed about the indi-
cations for and the timing of the surgery, risks of anticoagulant
therapy, and the potential need for and risk of reoperation in a
shared decision-making process that accounts for the patient’s
values and preferences. Both patients and clinicians are
reported to ﬁnd shared decision-making important but it is
not yet well implemented in clinical practice.20,21 The use of
patient decision aids to support the shared decision-making
process may be helpful in this regard. A recent randomized
trial showed that D23X Xthe use of a patient decision aid to support, Number 00 3
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patient knowledge, D24X Xpatients also feel better informed, less anx-
ious and depressed, and experienced a better mental quality of
life at the time of the decision-making.22
A recent study in Heart investigated through an online ques-
tionnaire Marfan patient and physician preferences for timing
of an intervention and the consequences of choosing valve-
sparing or valve-replacing strategies.23 They found that the
most important reported preferences were retaining an active
and participatory lifestyle, avoiding anticoagulation, and main-
tain as normal a life as possible. Patients were leaning toward
getting the surgery over with as soon as possible, while doctors
took a more conservative approach. The authors conclude that
people anticipating root replacement surgery should have
ample opportunity to express their viewpoints and to have
them acknowledged ahead of a consultation when they can
then be fully explored in a mutually informed forum. In line
with these observations, the Rotterdam group is in the process
of developing an information portal and decision aid for
patients with TAA (ZonMW project number 849200014).EVIDENCE-BASED AND SHARED TREATMENT
DECISION-MAKING IN THORACIC AORTIC
ANEURYSM: THE HOLY GRAIL?
From a clinician and a patient point of view, it seems that
combining (1) clinical evidence on outcomes, (2) the unique
clinical state and circumstances of the individual patient, and
(3) informed patient preferences in treatment decision-making
for TAA patients results in optimal clinical decision-making.
Given the value sensitive nature of the decisions that need to
be made regarding both the timing and the preferred surgical
treatment strategy in TAA patients, ample consultation time is
required. Unfortunately, in many health care systems, reim-
bursement is still largely based on the number of procedures
rather than the time spent in consultation concerning treat-
ment decision-making. However, times are slowly but surely
changing, with increasing emphasis in medicine on patient-
reported outcome measures and the implementation of patient
information portals and decision aids to support shared deci-
sion-making. It requires a different role pattern: for doctors to
take a more guiding role, and for patients to be proactive and
become a member of their own heart team. In this respect, the
introduction of decision aids in cardiovascular clinical practice
is not only effective in empowering patients, but may also help
to instruct clinicians on optimal implementation of shared
decision-making in their clinical practice.24 Especially for TAA
patients who face so many challenges related to their disease,
this will make a world of difference and allow for optimal tai-
loring of both the timing and the preferred treatment strategy
from a clinical and a patient perspective.REFERENCES
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